Insight Molecular Diagnostics reported Q1 2025 revenue of $2.138 million, marking a sharp year-over-year leap from $0.176 million in Q1 2024 and a 43.9% sequential increase from the prior quarter. The gross margin expanded to 61.97%, with gross profit of $1.325 million, underscoring a favorable product mix and early operating leverage, even as operating losses persisted. The company posted a net loss of $6.671 million and an EBITDA loss of $6.151 million, reflecting a heavy investment phase in R&D and go-to-market activities. Cash burn from operations was $5.858 million in the quarter, while financing activities provided $28.558 million, yielding a net cash increase of $22.393 million and ending cash around $32.7 million. From a balance-sheet perspective, Insight carries a modest debt load with a net cash position and strong liquidity ratios (current ratio ~3.75, quick ~3.70, cash ratio ~3.20). The quarter signals progress on revenue scale and margin, but the path to sustained profitability requires accelerated top-line growth and tighter cost control, which management guidance (if provided) and ongoing quarterly cadence will illuminate.